News and Insights
Canine Pilot Study — 26-Month Life Extension
WayPath's foundational research advanced from compound formulation through pre-clinical testing to a canine pilot study with compelling efficacy data. A pilot study in a canine diagnosed with Hemangiosarcoma (HSA) demonstrated a 26-month life extension following daily oral administration — far exceeding the 2-week median survival expected without treatment.
Announcements
September 2022 — Awarded NIH STTR Phase I grant, validating the scientific merit of PP211.
July 2024 — Introductory meeting completed with NCI NExT Program; application in progress.
November 2025 — Submitted NIH STTR Phase II application.